Home > Oncology > ASCO GU 2022 > Urothelial Carcinoma > Neoadjuvant enfortumab vedotin promising in MIBC ineligible for cisplatin

Neoadjuvant enfortumab vedotin promising in MIBC ineligible for cisplatin

Presented By
Prof. Daniel Petrylak, Yale School of Medicine, CT, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASCO GU 2022
Trial
Phase 1/2, EV-103
Results from the phase 1b/2 EV-103 trial showed promising anti-tumour activity of neoadjuvant enfortumab vedotin in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin therapy. Up to 1 in 4 patients diagnosed with urothelial cancer present with muscle-invasive disease, which has a substantial risk of progression or metastasis. Neoadjuvant chemotherapy has been shown to prolong overall survival for patients who are cisplatin-eligible [1]. The standard of care for cisplatin-ineligible patients undergoing surgery does not include neoadjuvant therapy. Enfortumab vedotin is an antibody-drug conjugate directed to Nectin-4, which is highly expressed in urothelial cancer and has been shown to benefit locally advanced or metastatic urothelial pre-treated cancer patients, including cisplatin-ineligible patients [2]. Cohort H of the EV-103 phase 1b/2 trial (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on